- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-MCL1
MCL1 Polyclonal Antibody for WB, IHC, IF/ICC, FC (Intra), IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, rat, souris
Applications
WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA
Conjugaison
Non conjugué
N° de cat : 16225-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | cellules Jurkat, cellules A431, cellules HEK-293T, cellules HeLa, cellules HL-60, cellules K-562, cellules MCF-7, cellules Raji, tissu cérébral humain, tissu hépatique humain, tissu splénique de souris | 
| Résultats positifs en IP | cellules Raji | 
| Résultats positifs en IHC | human ovary cancer tissue, il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. | 
| Résultats positifs en IF/ICC | cellules MCF-7, | 
| Résultats positifs en FC (Intra) | cellules Ramos | 
Dilution recommandée
| Application | Dilution | 
|---|---|
| Western Blot (WB) | WB : 1:1000-1:8000 | 
| Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate | 
| Immunohistochimie (IHC) | IHC : 1:50-1:500 | 
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 | 
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.50 ug per 10^6 cells in a 100 µl suspension | 
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 11 publications below | 
| WB | See 135 publications below | 
| IHC | See 16 publications below | 
| IF | See 7 publications below | 
| IP | See 7 publications below | 
| CoIP | See 1 publications below | 
Informations sur le produit
16225-1-AP cible MCL1 dans les applications de WB, IHC, IF/ICC, FC (Intra), IP, CoIP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris
| Réactivité | Humain, rat, souris | 
| Réactivité citée | rat, Humain, souris | 
| Hôte / Isotype | Lapin / IgG | 
| Clonalité | Polyclonal | 
| Type | Anticorps | 
| Immunogène | MCL1 Protéine recombinante Ag10397 | 
| Nom complet | myeloid cell leukemia sequence 1 (BCL2-related) | 
| Masse moléculaire calculée | 350 aa, 37 kDa | 
| Poids moléculaire observé | 35-40 kDa | 
| Numéro d’acquisition GenBank | BC107735 | 
| Symbole du gène | MCL1 | 
| Identification du gène (NCBI) | 4170 | 
| Conjugaison | Non conjugué | 
| Forme | Liquide | 
| Méthode de purification | Purification par affinité contre l'antigène | 
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol | 
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. | 
Informations générales
MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumour malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target. MCL-1 can be alternatively spliced into a long form (MCL-1L, 40 kDa) or a short form (MCL-1S, 30 kDa). (PMID: 15467463, PMID: 15147382)
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for MCL1 antibody 16225-1-AP | Download protocol | 
| IHC protocol for MCL1 antibody 16225-1-AP | Download protocol | 
| IF protocol for MCL1 antibody 16225-1-AP | Download protocol | 
| IP protocol for MCL1 antibody 16225-1-AP | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 
Publications
| Species | Application | Title | 
|---|---|---|
| Mol Cell The mitochondrial DNAJC co-chaperone TCAIM reduces α-ketoglutarate dehydrogenase protein levels to regulate metabolism | ||
| Nat Commun MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. | ||
| Nat Commun Small-molecule suppression of calpastatin degradation reduces neuropathology in models of Huntington's disease. | ||
| Nat Commun IFN-β is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation. | ||
| EBioMedicine The LIV-1-GRPEL1 axis adjusts cell fate during anti-mitotic agent-damaged mitosis. | ||
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
| FH Eya (Verified Customer) (07-06-2021) | the bands appear very clear 
 | 














